Research graph
References from Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction. Local targets link to admitted publications; unresolved targets remain external evidence.
Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism
10.1212/wnl.0000000000209453 · 2024 · External reference
10.1016/s1474-4422(23)00405-2
10.1016/s1474-4422(23)00405-2 · External reference
10.1016/j.abb.2013.12.020
10.1016/j.abb.2013.12.020 · External reference
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
10.1038/s43587-023-00478-y · 2023 · External reference
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders
10.1038/s41591-026-04212-0 · 2026 · External reference
Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts
10.1002/mds.29835 · 2024 · External reference
A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson’s disease with potential prognostic value
2026 · External reference
The Parkinson’s progression markers initiative (PPMI)–establishing a PD biomarker cohort
10.1002/acn3.644 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1212/wnl.0b013e3181c47cc2
10.1212/wnl.0b013e3181c47cc2 · External reference
10.1007/s00259-006-0357-2
10.1007/s00259-006-0357-2 · External reference
10.1111/j.1468-1331.2010.03246.x
10.1111/j.1468-1331.2010.03246.x · External reference
Striatal Dopamine Loss in Early Parkinson’s Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging
10.1002/mdc3.13687 · 2023 · External reference
Mechanisms of peripheral levodopa resistance in Parkinson’s disease
10.1038/s41531-022-00321-y · 2022 · External reference
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
10.1038/s41531-021-00172-z · 2021 · External reference
Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson’s disease
10.1016/j.ebiom.2026.106354 · 2026 · External reference
10.1038/s41531-026-01435-3
10.1038/s41531-026-01435-3 · External reference
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
10.1038/s41467-025-56293-z · 2025 · External reference
Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease
10.1002/ana.26373 · 2022 · External reference
Frontostriatal and limbic contributions to cognitive decline in Parkinson’s disease
10.1111/jon.13045 · 2023 · External reference
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer’s disease
10.1038/s41467-023-41122-y · 2023 · External reference
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
10.1186/s40035-023-00374-w · 2023 · External reference
10.1586/14737159.8.4.479
10.1586/14737159.8.4.479 · External reference
10.1016/j.mcpro.2023.100629
10.1016/j.mcpro.2023.100629 · External reference
10.1101/2025.09.25.25336658
10.1101/2025.09.25.25336658 · External reference
EANM practice guideline / SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
10.1007/s00259-020-04817-8 · 2020 · External reference
